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TRANSLATIONAL PHYSIOLOGY
Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes
insipidus in a polarized cell model
J. H. Robben,1 N. V. A. M. Knoers,2 and P. M. T. Deen1
1Department of Physiology, Nijmegen Centre for Molecular Life Sciences, and 2Department of
Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
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Robben, J. H., N. V. A. M. Knoers, and P. M. T. Deen.
Characterization of vasopressin V2 receptor mutants in nephrogenic
diabetes insipidus in a polarized cell model. Am J Physiol Renal
Physiol 289: F265–F272, 2005; doi:10.1152/ajprenal.00404.2004.—
X-linked nephrogenic diabetes insipidus (NDI) is caused by mutations
in the gene encoding the vasopressin V2 receptor (V2R). For the
development of a tailored therapy for NDI, knowledge of the cellular
fate of V2R mutants is needed. It would be useful when this fate could
be predicted from the location and type of mutation. To identify
similarities and differences in localization, maturation, stability, and
degradation of COOH-terminal GFP-tagged V2R mutants, we stably
expressed nine mutants in polarized Madin-Darby canine kidney cells.
The mutants V2R-L44P, -62–64, -I130F, -S167T, -S167L, and
-V206D were mainly expressed in the endoplasmic reticulum (ER) as
immature proteins. These mutants had relatively short half-lives due
to proteasomal degradation, except for V2R-62–64. In contrast,
V2R-R113W, -G201D, and -T204N were expressed in the ER and in
the basolateral membrane as immature, high-mannose glycosylated,
and mature complex-glycosylated proteins. The immature forms of
V2R-R113W and -T204N, but not V2R-G201D, were rapidly de-
graded. The mature forms varied extensively in their stability and
were degraded by only lysosomes (V2R-T204N and wild-type V2R)
or lysosomes and proteasomes (V2R-G201D, -R113W). These data
reveal that most missense V2R mutations lead to retention in the ER
and suggest that mutations that likely distort a transmembrane domain
or introduce a charged amino acid close to it make a V2R mutant more
prone to ER retention. Because six of the mutants tested showed
significant increases in intracellular cAMP levels on transient expres-
sion in COS cells, activation of these six receptors following rescue of
cell-surface expression might provide a cure for NDI patients.
G protein-coupled receptors; endoplasmic reticulum; Madin-Darby
canine kidney cells; protein degradation
TO INCREASE RENAL WATER REABSORPTION in states of hypernatre-
mia or hypovolemia, pituitary-released arginine-vasopressin
(AVP) binds to its vasopressin V2 receptor (V2R) in the
basolateral membrane of polarized principal cells. This inter-
action induces the binding, activation, and cleavage of a
trimeric Gs protein, of which the stimulatory s-subunit acti-
vates adenylate cyclase to generate cAMP. Through several
steps, this eventually redistributes aquaporin-2 (AQP2) water
channels from intracellular vesicles into the apical membrane,
rendering this membrane permeable to water. Following an
osmotic gradient over the epithelium, water can then be reab-
sorbed from the prourine to the blood.
In the rare inheritable disorder nephrogenic diabetes insipidus
(NDI), patients are unable to concentrate their urine in response to
AVP, resulting in the excretion of large volumes of dilute urine.
Mutations in the AVPR2 gene have shown to be causative for
90% of all NDI cases and are inherited in an X-linked fashion.
Autosomal NDI, either recessive or dominant, accounts for the
remaining 10% of cases and is caused by mutations in the AQP2
gene (10). To date, over 180 mutations have been described in
the AVPR2 gene, most of them being missense mutations.
Because an effective treatment of patients depends on the
cellular defect introduced by the mutation, Zeitlin (27) classi-
fied mutations of the cystic fibrosis transmembrane conduc-
tance regulator gene into five different classes according to
their cellular fate. Recently, we adapted this classification to G
protein-coupled receptors in general and the V2R in particular
(5). In this classification, class I mutations lead to defects in the
synthesis of stable mRNA, resulting in the absence of protein.
Promoter alterations, aberrant splicing, exon skipping, and
most frame-shift and nonsense mutations fall into this cate-
gory. Class II mutations lead to fully translated proteins, but
they are trapped in the endoplasmic reticulum (ER), as they are
misfolded. Class III mutants are normally transported to their
site of action, but at that location they are disturbed in their
activation or regulation. For the V2R, mutations on the cyto-
solic side of the protein that interfere with G protein binding
and thus prevent intracellular signaling, like the R137H muta-
tion (22), fall into this category. Class IV mutations also do not
affect protein trafficking, but they impair or decrease the
receptor’s ability to bind ligand, as has been reported for
V2R-R202 (1) and V2R-R181C (19). Finally, class V muta-
tions lead to proteins that are not disturbed in any of the above
ways but are missorted to another organelle in the cell.
Knowledge of the cellular and molecular cause of mutant
proteins in diseases is essential for the development of ratio-
nally based treatment. To prevent laborious cell biological
analyses of all mutants, a prediction of the cellular fate of the
mutant protein made on the basis of the identified mutation
would be useful. However, for mutant proteins in general and
the V2R in particular, it is at present unclear whether particular
amino acid substitutions or locations of the mutations within
the protein make the mutant likely to be of a particular class. In
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addition, most data on the cellular cause of V2R mutants in
NDI have been obtained from transiently transfected cells.
Although possibly useful, these cells are not polarized, as renal
principal cells, and proteins may rout differently from polar-
ized cells (13). Moreover, due to the high expression levels in
transient assays, the mutants are often expressed at several
sites, which make interpretation of the proper cellular location
difficult. Recently, we generated a Madin-Darby canine kidney
(MDCK) cell line in which exogenous V2R is expressed and
regulated by dDAVP as can be anticipated for the V2R in vivo
(21). To address the issues above, we selected nine V2R
mutations that cause NDI and are distributed along the V2R
protein. Subsequently, we stably expressed these V2R mutants
in MDCK cells and thoroughly analyzed their functionality,
localization, degradation pathway, and stability.
MATERIALS AND METHODS
Materials. MG-132 was from Calbiochem (La Jolla, CA); chloro-
quine diphosphate, cycloheximide, IBMX, and dDAVP were from
Sigma (St. Louis, MO). The pEGFP-N1-V2R plasmid encoding wild-
type (wt)-V2R, COOH terminally tagged with the green fluorescent
protein (GFP) (25), was kindly provided by Dr. Alexander Oksche
(FMP, Berlin, Germany).
Expression constructs. With a three-step PCR reaction or quick-
change site-directed mutagenesis kit (Stratagene, Heidelberg, Ger-
many), each mutation was introduced into the human V2R cDNA
sequence using pEGFP-N1-V2R as a template. Primers used were
CGCTGCCATCCATAGTCTTTGTGG for L44P, CTGGTGCTG-
GCGGCCCGGGGCCGGCGGGG for 62–64, CCTGTGTTGGGC-
CGTGAAGTATC for R113W, GCCTCCTCCTACATGTTCCTGGC
for I130F, CCTTCACACTCCTTCTCAGCCTGC for S167T, CCT-
TCTTGCTCCTTCTCAGCCTGC for S167L, CTGGGATCGTCG-
CACCTATGTCAC for G201D, GTCGCAACTATGTCACCTG-
GATTGC for T204N, and GTCGCACCTATGATACCTGGATTGC
for V206D, and their complementary antisense primers. After digest-
ing correct clones with BglII/PstI (L44P, 62–64, R113W) or PstI/
HindIII (I130F, R137H, S167T, S167L, G201D, T204N and V206D),
the mutation-containing fragments were isolated and cloned into the
corresponding sites of wt-V2R-GFP. Sequence analysis of selected
clones confirmed that only the desired mutations were introduced.
MDCK cells. MDCK cells were maintained and stably transfected,
and immunocytochemistry and confocal laser-scanning microscopy
(CLSM) were performed as described (7). As primary antibodies,
1:100-diluted rabbit anti protein disulfide isomerase (PDI; a kind gift
of Dr. I. Braakman, Utrecht, The Netherlands); 1:200-diluted mouse
anti-lysosome-associated membrane protein 2 (LAMP-2) antibodies
(15), a kind gift of Dr. Le Bivic, Marseille, France; or 1:100-diluted
rat anti E-cadherin (Sigma) were used. As secondary antibodies,
1:100-diluted goat anti-rabbit, goat anti-rat, or goat anti-mouse IgGs,
all three coupled to Alexa 594, were used (Molecular Probes, Leiden,
The Netherlands). Semiquantification of colocalization of V2R with
cellular markers was done as described (21).
Stability and degradation experiments. To determine receptor sta-
bility, cell lines were incubated for either 0, 2, 4, or 8 h in culture
medium containing 50 M cycloheximide to block protein synthesis,
after which the cells were lysed in 1 Laemmli sample buffer and
subsequently analyzed by immunoblotting. To determine the degra-
dation pathway of the receptors, cells were incubated in culture
medium containing 50 M cycloheximide, supplemented with 20 M
MG-132, 100 M chloroquine, or both. Cells incubated in normal
culture medium were used as controls. After 8 h, cells were lysed in 1
Laemmli sample buffer and subsequently analyzed by immunoblotting.
Immunoblotting. Protein samples were prepared and analyzed on a
10% polyacrylamide gel and subsequently blotted as described (7).
For detection of V2R-GFP, 1:5,000-diluted rabbit anti-GFP antiserum
(3) (kindly provided by Dr. B. Wieringa, UMCN, Nijmegen, The
Netherlands) or 1:20,000 mouse anti--actin (Sigma) was used. As
secondary antibodies, goat anti-rabbit or sheep anti-mouse IgGs cou-
pled to horseradish peroxidase (Sigma) were used at a 1:5,000
dilution. Immunoblot signals were semiquantified using Image-Pro
software (Media Cybernetics, Silver Spring, MD) as described (21).
Data of at least three experiments were used for quantification.
cAMP measurement, [3H]AVP binding, and cell-surface biotinyla-
tion. COS-M6 cells were seeded on six-well plates and grown to 80%
confluence. Subsequently, 5 g plasmid DNA encoding either wt or
mutant V2R-GFP were transfected into the cells using lipofectamine.
The next day, cells were seeded at 80% confluence and grown overnight
in DMEM with 10% fetal calf serum in a humidified 37°C incubator
under 5% CO2. The cells were subsequently treated with prewarmed
medium containing 100 nM dDAVP for 5 min in the absence of IBMX.
After the cells were washed briefly in prewarmed PBS-CM, the cells
were lysed in 100 l of 0.1 M HCl, and cAMP was measured using
a fluorescent cAMP assay kit (Sigma) according to the manufacturer’s
protocol. Assay plates were read in the Model 3550-UV Microplate
Reader (Bio-Rad, Hercules, CA) using an excitation wavelength of
405 nm. Measurements were performed at least in triplicate.
For radioligand binding assays, transfected COS-M6 cells were
grown overnight, seeded at a density of 5.0  105 cells/cm2 on
12-well plates, and again grown overnight. Radioligand labeling was
performed as described (21). Averaged data of at least three indepen-
dent experiments were used.
For cell-surface biotinylation, transfected COS-M6 cells were
grown for 2 days and subsequently biotinylated as described (7).
Instead of filters, COS-M6 cells were grown on plastic supports.
Statistical analyses. All statistical analyses were calculated using
MS Excel. The spread of values is indicated as SD. Significance was
calculated by performing Student’s t-test.
RESULTS
Localization of the V2R mutants. The nine V2R mutations,
i.e., L44P, R113W, S167L, T204N, V206D (11), 62–64 (2),
I130F (20), S167T (17), and G201D (23), which are dispersed
over the V2R protein (Fig. 1), have been shown to cause NDI.
In MDCK type I cells, the localization, maturation, and
dDAVP-induced internalization of V2R-GFP mimic that an-
ticipated for V2R in principal cells to a great extent (21).
Therefore, we stably transfected MDCK cells with expression
constructs encoding the V2R-GFP mutants mentioned. Multi-
ple positive clones were isolated for each mutant. Immunocy-
tochemistry and subsequent confocal laser-scanning micro-
scopic analysis of V2R-S167L and -I130F showed a nearly
complete colocalization with the ER marker PDI (Fig. 2, top).
Semiquantification revealed a colocalization of 94.1  4.5 and
94.3  4.2%, respectively. The mutants V2R-L44P (92.4 
5.1%), -62–64 (94.4  3.4%), -S167T (92.3  3.9%), and
-V206D (95.7  3.6%) showed similar results (not shown).
Confocal analysis of V2R-R113W and -G201D (Fig. 2,
middle), however, showed only a partial colocalization with the
ER marker PDI (53.3  5.5 and 50.3  8.5%, respectively).
The remainder colocalized with the basolateral marker E-
cadherin in the lateral membrane (44.8 6.9 and 46.1 8.1%,
respectively) or with the late endosomal/lysosomal marker
LAMP-2 (4.2  2.4 and 5.6  3.1%; not shown). Similar
results were obtained for V2R-T204N (51.3  7.9% with PDI;
43.2  5.1% with E-cadherin; 5.1  2.3% with LAMP-2; not
shown). As reported (21), wt-V2R was expressed predomi-
nantly in the lateral plasma membrane of MDCK cells (75%),
and to a lesser extent in late endsomes/lysosomes (25%), and
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did not show any colocalization with the ER marker protein
(Fig. 2, bottom).
Maturation state of the V2R mutants. To test the maturation
states of the different V2R mutants, total cell lysates were
undigested, digested with endoglycosidasde H (Endo H),
which removes N-linked high-mannose sugar groups, or with
PNGase F, which removes all N-linked sugar moieties, and
immunoblotted. Recently, we have reported that V2R-GFP is
mainly expressed as complex-glycosylated proteins of 75 kDa
(Fig. 3, bottom) (21). With Endo H, the majority remained
unaffected, whereas some 60-kDa core-glycosylated V2R ap-
peared. With PNGase F, the 75-kDa band was reduced to 67
kDa, which might represent O-glycosylated V2R.
Western blot analysis of undigested V2R-S167L (Fig. 3, top
left) showed a strong 60-kDa core protein and a second band of
63 kDa. This latter band disappeared with Endo H (and
PNGase F) digestion, which indicated that this band represents
high-mannose glycosylated V2R-GFP. These data suggested
that most, if not all, V2R-S167L is retained in the ER. Similar
results were obtained for V2R-L44P, -62–64, -S167T, and
-V206D (not shown).
V2R-I130F was also mainly expressed as 60- and 63-kDa
bands, although weak bands of 67 and 75 kDa were ob-
served (Fig. 3, top right). Upon digestion with Endo H, the
weak 75-kDa and strong 60-kDa bands remained, whereas a
faint band of 65 kDa appeared. The 63-kDa band disap-
peared with Endo H. With PNGase F, a weak 67-kDa band
and strong 60-kDa band were observed. The presence of the
weak 75-, 65-, and 67-kDa bands indicated that a small
fraction of V2R-I130F has left the ER and was partially (65
Fig. 1. Location of mutations in vasopressin
V2 receptor (V2R) protein. Topological map
of the human V2R is shown. Mutated resi-
dues are indicated in black; introduced
amino acids are indicated by arrows.
Fig. 2. Localization of nephrogenic diabetes
insipidus (NDI) causing V2R mutants. Ma-
din-Darby canine kidney (MDCK) cell lines
stably expressing V2R-S167L, -I130F,
-R113W, -G201D, or wild-type V2R were
grown to confluence and fixed. Immunocy-
tochemistry was done for protein disulfide
isomerase (PDI) to stain the endoplasmic
reticulum (ER). Signals for PDI and the V2R
are shown in red and green, respectively.
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kDa with Endo H) or fully (75 kDa; 67 kDa with PNGase F)
matured.
Analysis of the maturation of V2R-R113W revealed similar
bands as those observed for V2R-I130F, except here the bands
of 75 (control and endo H) and 67 (PNGase F) kDa were
stronger for V2R-R113W (Fig. 3, middle left). V2R-G201D
was even more mature, because the 75- and 67 (PNGase
F)-kDa bands were of similar intensity as the core form (Fig. 3,
middle right). Similar data as for V2R-G201D were obtained
for V2R-T204N (not shown). Semiquantification of the signals
confirmed the differences in maturation, because data for
V2R-I130F, -R113W, -G201D, and -T204N show that 7.3 
4.1, 59.2  5.9, 64.3  7.1, and 66.6  4.5% were expressed
as 75-kDa proteins, respectively (n  3), whereas the remain-
der comprises core- and high-mannose glycosylated proteins.
These data demonstrate that the mutants V2R-R113W,
-G201D, and -T204N are only partially retained in the ER and
that a considerable proportion undergoes maturation. Similar
patterns were observed for transfected clones with different
expression levels of these mutants (not shown), indicating that
the observed differences in maturation were related to the
mutation and not due to clonal differences in expression levels.
Stability of V2R mutants. As introduced mutations may
affect the stability of proteins, we determined the half-lives
(t1⁄2) of the V2R mutants. Following a protein synthesis block
with cycloheximide, the total V2R content of the cells was
monitored over time. V2R-S167L (Fig. 4, first panel) showed
a rapid decrease in its 60/63-kDa bands (here, they run as 1
band). Semiquantification of the signals (n  3) revealed a t1⁄2
of 1.5  0.4 h for V2R-S167L. The t1⁄2 of V2R-L44P (1.5 
0.3 h), -S167T (2.4  0.4 h), and -V206D (3.2  0.7 h) were
in the same range (not shown). The 60/63-kDa bands of
V2R-62–64, however, were much more stable, as it has a
calculated t1⁄2 of 12.5  3.4 h (Fig. 4, second panel). The
mutant V2R-I130F (Fig. 4, third panel) also showed a rapid
decrease in its 60/63-kDa bands, from which we calculated a t1⁄2
of 1.9  0.5 h. We were not able to quantify the stability of
V2R-I130F’s complex-glycosylated form, as this signal was
too weak for this analysis.
As V2R-R113W, -G201D, and -T204N are expressed as
core-glycosylated (60/63 kDa) and complex-glycosylated (75
kDa) proteins, we analyzed the stability of both forms. Semi-
quantification revealed that complex-glycosylated V2R-
R113W had a t1⁄2 of 14.4  3.2 h. In contrast, the 60/63-kDa
form had a t1⁄2 of only 2.1  0.3 h. For V2R-G201D, the t1⁄2of
the complex-glycosylated form was only 4.1 1.5 h. Although
a rapid decrease is observed during the first 2 h for the
high-mannose glycosylated V2R-G201D, hardly any degrada-
tion is observed beyond this period, leading to a calculated t1⁄2
of 10.2  3.0 h. For V2R-T204N, the t1⁄2 of the complex-
glycosylated form and the high-mannose glycoyslated form
were 2.2  0.6 and 2.1  0.2 h, respectively (Fig. 4, sixth
panel). Again, similar t1⁄2 were obtained from two independent
clones per construct, indicating that the differences in t1⁄2 are
not due to clonal differences. As reported, wt-V2R has a t1⁄2 of
11.5  2.8 h (21).
Fig. 3. Maturation of NDI causing V2R mutants. To determine the glycosyl-
ation state of V2R-S167L, -I130F, -R113W, -G201D, or wild-type (wt)-V2R
(indicated), confluent MDCK-V2R-green fluorescent protein (GFP) cells were
lysed in Laemmli buffer, treated without any enzyme (control), or with Endo
H or PNGase F, and analyzed by immunoblotting using anti-GFP antibodies.
Estimated masses (in kDa) are given on the left.
Fig. 4. Stability of NDI causing V2R mutants. MDCK cells expressing
V2R-S167L, -62–64, -I130F, -R113W, -G201D, -T204N, or wt-V2R were
grown to confluence and subsequently treated with 50 M cycloheximide to
block protein synthesis. At the indicated time points (h), cells were lysed in
Laemmli sample buffer and analyzed by immunoblotting as indicated in the
legend for Fig. 3. Estimated masses (in kDa) are given on the left.
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Degradation pathway of the V2R mutants. Proteins can be
degraded by the proteasomal pathway, which can be inhibited
by MG-132, or the lysosomal pathway, which is inhibited by
chloroquine and, sometimes, MG-132. Considering the differ-
ences in stability of the mutants, we next studied their degra-
dation pathways by incubating the cells for 8 h with cyclohex-
imide alone or combined with MG-132, chloroquine, or both.
As shown in Fig. 5 (first and second panels), the degradation of
V2R-S167L and -I130F was nearly completely prevented by
MG-132, whereas chloroquine had no effect on its own, nor in
combination with MG-132. Similar results were obtained for the
mutants V2R-L44P, -62–64, -S167T, and -V206D (not shown).
The degradation of the complex-glycosylated bands of V2R-
R113W was partially prevented by coincubation with either
chloroquine or MG-132 (Fig. 5, third panel). Incubation with
both inhibitors revealed no degradation at all. Strikingly, of the
two most prominent bands of complex-glycosylated V2R-
R113W, chloroquine stabilized the larger form, whereas MG-
132 treatment mainly prevented degradation of the lower band.
The 60/63-kDa band was only partially prevented from degra-
dation by the combination of MG-132 and chloroquine.
For V2R-G201D (Fig. 5, fourth panel), chloroquine treat-
ment did not prevent degradation of the high-mannose or
complex-glycosylated form. MG-132, however, prevented
degradation of both, resulting in similar protein levels as found
in the untreated sample. Combined treatment of chloroquine
and MG-132 did not show an additional effect compared with
MG-132 alone. For V2R-T204N (Fig. 5, fifth panel), cyclo-
heximide treatment resulted in decreased V2R protein levels of
both the complex- and the 60/63-kDa forms. Chloroquine
treatment completely prevented degradation of the complex-
glycosylated form of V2R-T204N but did not prevent degra-
dation of the 60/63-kDa forms. MG-132 partially prevented the
degradation of the complex-glycosylated form (14%), and
completely prevented the degradation of the 60/63-kDa forms
of the V2R-T204N. Combined MG-132/chloroquine treatment
did not result in 	60/63-kDa or complex-glycosylated V2R-
T204N compared with MG-132 or chloroquine alone. Degra-
dation of the complex-glycosylated form of the wt-V2R (Fig.
5, fifth panel) could completely be prevented by cotreatment
with chloroquine, whereas MG-132 was able to prevent deg-
radation of the high-mannose glycosylated form.
Receptor functionality. To assess which V2R mutants are
functional, the mutant’s ability to generate cAMP in response
to a dDAVP treatment was determined. As MDCK type I cells
express low levels of endogenous V2R (6, 21), receptor func-
tionality assays were performed in COS cells, as these cells do
not endogenously express V2Rs. Furthermore, to obtain some
mutant receptor expressed at the cell surface, these cells were
transiently transfected, as this mostly gives high expression
levels. As shown in Fig. 6A, dDAVP binding of the mutants
V2R-L44P, -R113W, -I130F, -S167T, -G201D, and -T204N
resulted in significantly increased cAMP levels compared with
mock-transfected cells (P 
 0.001; n  3), indicating that
these mutants can translate AVP binding into a cAMP response.
The mutants V2R-62–64, -S167L, and -V206D showed no
significant cAMP increase compared with mock-transfected cells.
Because the expression of these three mutants was similar to or
greater than that of functional V2R-S167T (Fig. 6B) and they
have similar localizations and maturation characteristics (Figs.
2 and 3), these three mutants were likely to be interfered with
in their binding to dDAVP or activating a Gs protein.
To investigate this further, COS cells expressing V2R-GFP,
V2R-62–64, -S167L, -V206D, and the functional mutants
V2R-L44P or -I130F were subjected to radioligand binding
assays. As shown in Fig. 6C, V2R-L44P, -I130F, and -62–64
bind significantly more [3H]AVP than mock-transfected cells
(P 
 0.001; n  3). No significant binding was observed for
cells expressing V2R-S167L and -V206D (P	 0.05; n3).
V2R-GFP-expressing cells bound radioligand to 19,619 
2,453 counts (not shown).
Because the lack of AVP binding and cAMP generation
could be due to the lack of expression in the plasma membrane,
transfected COS cells were subjected to cell-surface biotinyla-
tion assays. Immunoblotting of the obtained samples, however,
revealed that the plasma membrane expression levels of the
non-AVP binding receptors V2R-S167L and V2R-V206D
were clearly higher than that of the functional V2R-L44P (Fig.
6D). In these biotinylation samples, no signals for -actin were
observed (Fig. 6D, bottom), whereas strong actin signals were
obtained in the corresponding lysate sample of COS cells
expressing wt-V2R (Fig. 6D) or the mutants (not shown). This
indicated that the biotinylation samples did not contain intra-
cellular proteins. Therefore, these data reveal that V2R-S167L
and V2R-V206D are unable to generate an intracellular cAMP
response due to their inability to bind AVP.
DISCUSSION
All V2R mutants are retained in the ER, but at different
levels. To study the cellular fate (summary in Table 1) of nine
V2R mutants involved in NDI, MDCK cells were stably
Fig. 5. Degradation pathways of NDI causing V2R mutants. Cell lines stably
expressing V2R-S167L, -I130F, -R113W, -G201D -T204N, or wt-V2R were
treated for 8 h as indicated. Western blot analysis was performed as described
in the legend for Fig. 3. Estimated masses (in kDa) are given on the left.
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transfected with expression constructs for these proteins.
CLSM analysis revealed that all mutants colocalized with the
ER marker protein PDI, indicating their retention in the ER.
The level of ER retention, however, differed among mutants.
Whereas the mutants V2R-L44P, -62–64, -S167T, -S167L,
and -V206D were restricted to the ER (group 1), a considerable
fraction of V2R-R113W, -G201D, and -T204N was expressed
in the basolateral membrane (group 2; Fig. 2). Their level of
maturation was consistent with the observed localizations, as
the members of group 1 were only expressed as nonglycosy-
lated 60-kDa or core-glycosylated 63-kDa proteins, whereas
the group 2 receptors were expressed as immature 60/63-kDa
proteins and mature complex-glycosylated proteins (Fig. 3).
Pronounced ER retention has also been reported for V2R-62–64
and -S167L in HEK293 cells (9) and for the V2R mutants L292P,
V278, and R337X in polarized MDCK cells (26).
An exception is formed by V2R-I130F, which seemed re-
stricted to the ER with immunocytochemistry, but of which
immunoblot data of Endo H or PNGase F digestions revealed
a small fraction of intermediate or complex-glycosylated re-
ceptor. Of V2R-I130F, only 7.3% is expressed in a mature
form, whereas 60–70% of V2R-R113W, -G201D, and -T204N
is expressed in the mature form. Therefore, mature V2R-I130F
may possibly be present in the basolateral membrane at levels
that could not be detected by immunocytochemistry. Taken
together, these data indicate that the level of ER retention and
maturation of V2R-I130F is in between that of the two groups.
Our finding that all mutants are, at least partially, retained in
the ER illustrates the high sensitivity of the ER quality control
mechanism to identify mutant proteins. Strikingly, based on the
proposed topology of the V2R (24), all V2R mutations leading
to strong ER retention are located in either one of the trans-
membrane domains (TMD; L44P, I130F, S167T, S167L) or
change a hydrophobic into a charged amino acid at the edge of a
TMD (L into R in V2R-62–64, V206D). These mutations might
interfere with the proper folding or positioning of the hydrophobic
TMDs, of which luminal or cytosolic exposure is thought to
render proteins prone to recognition by the ER quality control
mechanism, ER retention, and subsequent degradation (8, 12).
The slightly better maturation of V2R-I130F compared with the
others might be due to an exchange of a hydrophobic amino acid
for another in the TMD of V2R-I130F. In contrast, with V2R-
Fig. 6. Functionality of NDI causing V2R mutants. A: cAMP generation. COS-M6 cells transiently expressing either wt-V2R or mutant V2R proteins were
treated for 5 min with 100 nM dDAVP, washed in PBS-CM, and lysed in 0.1 M HCl, followed by cAMP measurement in a fluorescence-based assay.
*Significantly different from mock-transfected cells (P 
 0.001); n  3. B: V2R protein expression levels. Cell equivalents from the experiment in A were
lysed in Laemmli buffer and subjected to immunoblotting as described in the legend for Fig. 3. C: AVP binding. Transiently transfected COS cells were incubated
for 1 h at 4°C with 100 nM [3H]AVP in PBS-CM followed by washing, scraping, and counting in a scintillation counter. *Significant difference in radioligand
binding compared with mock-transfected cells (P 
 0.01); n  3. D: cell-surface expression of V2R proteins. Transiently transfected COS cells from C were
subjected to cell-surface biotinylation. Cell-surface proteins were subjected to immunoblotting for V2R (top) or -actin (bottom) as described in the legend for
Fig. 3. As a control for the antibodies, the far right lane contains a total lysate sample of COS cells expressing wt-V2R.
Table 1. Localization, maturation, functionality, and classification of wild-type and mutant V2R
L44P 62–64 S167T S167L V206D I130F R113W G201D T204N wt-V2R
Location of mutation TM I ICL 1 TM IV TM IV ECL 2 TM III ECL 1 ECL 2 ECL 2 NA
Cellular localization ER ER ER ER ER ER ER, PM, LE ER, PM, LE ER, PM, LE PM, LE
Glycosylation HM HM HM HM HM HM/(C) HM/C HM/C HM/C C
Half-life, h 1.5 12.5 2.4 1.5 3.2 1.9 2.1/14.4 10.2/4.1 2.1/2.2 11.5
Degradation MS MS MS MS MS MS MS/CS MS/CS MS/CS CS
AVP binding   NA    NA NA NA 
cAMP response          
Mutant class II II II II II II II and IV II and IV II and IV
Shown is a summary of the data from Figs. 1–6. V2R, vasopressin V2 receptor; TM, transmembrane domain; ICL, intracellular loop; ECL, extracellular loop;
PM, plasma membrane; LE, late endosomes and lysosomes; ER, endoplasmic reticulum; C, complex-glycosylated; HM, high-mannose glycosylated; MS,
MG132-sensitive degradation; CS, chloroquine-sensitive degradation; wt, wild-type; NA, nonapplicable. Mutants were classified according to Deen et al. (5).
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L44P, the introduced proline is likely to introduce a knick and
therefore distort the -helical structure of TMDI.
Our finding that V2R mutants, mutations of which are located
in the third extracellular loop (G201D and T204N) or introduce a
hydrophobic amino acid at the edge of the first extracellular loop
and TMD III (R113W), suggests that mutations located on the ER
luminal side of V2R are causing less severe misfolding of the
receptor protein compared with mutations in the TMD. Alterna-
tively, they might be less well recognized by ER quality control
proteins than transmembrane or cytosolic segments. Definite an-
swers to these issues can only be given when the atomic structure
of the V2R has been elucidated.
Stability and degradation of V2R mutants. To further study
the fate of the V2R mutant proteins, their stability and degra-
dation pathways were investigated (Figs. 4 and 5; Table 1).
Compared with the t1⁄2 of complex-glycosylated wt-V2R, the
stability of ER-retained mutants in general was drastically
reduced (up to 8.5-fold). Also, degradation of the ER-retained
V2R forms (60/63 kDa) occurred for most mutants through the
proteasomal pathway, as MG-132, which interferes with pro-
teolysis by the proteasome, greatly stabilized most 60/63-kDa
V2R mutants. These data are consistent with the current view
that wt or mutant proteins targeted for degradation from the ER
are processed via the so-called ER-associated degradation
(ERAD) pathway, which involves the recognition of misfolded
proteins by molecular chaperones, their transport from the ER
to the cytoplasm through an ER translocon, and degradation in
the cytosol by proteasomes. V2R-G201D and V2R-62–64
seem to form exceptions to this rule. Although a considerable
portion of the 60/63-kDa V2R-G201D proteins was degraded
within 2 h, a small fraction appeared very stable (8 h; Fig. 5).
This might indicate that, whereas most V2R-G201D is recog-
nized as misfolded and degraded, a small portion might be
resistant to recognition by molecular chaperones, transport
from the ER and/or degradation by proteasomes. More inter-
esting, however, the t1⁄2 of V2R-62–64 was similar to that of
wt-V2R. Because this is the only mutant in which amino acids
are deleted instead of exchanged, it might suggest that the
ERAD pathway is more sensitive to missense mutations than to
a lack of amino acids. Alternatively, because we only studied
one deletion mutant, the difference might be just coincidental.
Therefore, analysis of more V2R deletion mutants is required
to address this issue.
For the complex-glycosylated forms of the mutants (i.e.,
V2R-R113W, -G201D, -T204N), the stability and degradation
pathways vary considerably and appear unrelated to the stabil-
ity and degradation pathways acting on the immature receptors.
Mature V2R-GFP was degraded only by the proteasomal
pathway, as only chloroquine inhibited its degradation. V2R
tagged at its NH2 terminal with an HA tag showed a similar
stability (t1⁄2  12.2  3.8 h) and degradation pathway to
V2R-GFP (not shown), which indicated that neither the tag
(GFP or HA) nor its site of coupling (NH2 or COOH terminal)
affected V2R degradation. This was different for the V2R
mutants. While V2R-T204N is also only degraded by the
lysosomal pathway, V2R-R113W degradation was inhibited by
MG-132 and chloroquine, whereas V2R-G201D degraded was
only inhibited by MG-132. These results might indicate that
mutations that are located at the luminal side of the membrane
can induce the degradation of mature V2R by proteasomes,
which are thought to degrade proteins from the cytosolic side.
Alternatively, these V2R mutants are also degraded in lyso-
somes, as MG-132 is also a highly potent inhibitor of various
cysteine proteases and cathepsins (29, 30). The degradation
pathway used for the mature mutants, however, does not
appear to be indicative of their stability, because V2R-G201D
and V2R-T204N are three to six times less stable than wt-V2R,
whereas mature AQP2-R113W is as stable as wt-V2R. Com-
plex-glycosylated proteins are formed from core-glycosylated
proteins in the Golgi complex and, therefore, the observed
stabilities of the V2R proteins might be overestimated. Along
the same line, the observed high stability of V2R-R113W
compared with V2R-G201D and -T204N might be due to a
higher level of immature V2R-R113W processed through the
Golgi complex. Although this cannot be excluded, the similar
or low stability of immature V2R-R113W compared with those
of V2R-G210D and -T204N render this possibility rather
unlikely. More likely, the observed differences are due to
different impacts of the mutations on the structure of the V2R.
How mature V2R mutants are targeted for proteasomal and/or
lysosomal degradation, however, remains unclear.
Functionality of V2R mutants. All mutants tested, with the
exception of V2R-62–64, -S167L, and -V206D, showed
significantly increased cAMP levels compared with nontrans-
fected COS cells in a transient overexpression system and were
thus designated as being functional. Of the “non-functional”
mutants, only V2R-62–64 was able to bind AVP. V2R-
S167L and -V206D did not bind detectable levels of AVP,
although their membrane expression levels were higher than
that of the AVP-binding mutant V2R-L44P, which indicated
that the lack of V2R-S167L and -V206D to mediate a cAMP
response is due to a reduced ability to bind AVP. In contrast to
our study, Morello et al. (14) found a cAMP response with
rescued V2R-62–64. This discrepancy might be caused by
their use of the PDE inhibitor IBMX, their 100-fold higher
dDAVP concentration, the longer cAMP accumulation time
(20 vs. 5 min here), and/or increased expression of this mutant
receptor due to its rescue to the cell surface by the V2R
antagonist SR121463A. Both data, however, are in line with
the hypothesis of Oksche et al. (16) that the first intracellular
loop of the V2R is involved in Gs protein binding and that this
is greatly reduced by the 62–64 mutation, thereby reducing
the activation of adenylate cyclase. With the V2R-V206D
mutant, there is a discrepancy between our data and the data
from Postina et al. (20a), who observed a residual cAMP
formation upon stimulation, but no AVP binding. Here, it
might be due to the higher amount of DNA in their transient
COS transfection experiments (1 g DNA/cm2 compared
with 0.5 g DNA/cm2), the presence of IBMX, the long
incubation time with dDAVP (40 min compared with 5 min),
and/or the higher dDAVP concentration used (1 M). How-
ever, our data are consistent with the computer model of
Czaplewski et al. (4), which hypothesizes that V206 is impor-
tant for AVP binding.
Classification of mutations in the V2R. In line with our cell
biological data, patients encoding V2R mutants that are se-
verely ER retarded in our cell model (V2R with L44P, 62–
64, I130F, S167T, S167L, V206D) do not increase their urine
concentration in response to administration of dDAVP (2, 11,
18, 20). In contrast but consistent with the observed maturation
and partial basolateral membrane expression in MDCK cells,
patients encoding V2R-G201D (23) or -T204N (Knoers
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NVAM, unpublished observations) are able to increase their
urine concentrating ability on administration of a high dose of
dDAVP. For patients carrying the R113W mutation, no in-
creased urine concentrating ability after dDAVP administration
has been reported. Overall, these parallels with in vivo findings
provide further support that stably transfected polarized
MDCK cells are a good model for the study of the cell
biological features of wt and mutant V2R proteins.
In conclusion, our data reveal that all nine V2R mutations
studied are of class II, because all V2R mutants studied are
retained in the ER. The V2R-R113W, -G201D, and -T204N
mutants, however, are also partially expressed in the basolat-
eral membrane of MDCK cells and initiate a cAMP response
following AVP binding, which reveals that these mutations are
also of class IV. It has to be noted, however, that we cannot
exclude the possibility that the mutations studied result in
unstable V2R (pre-) mRNAs in vivo (i.e., class I mutations).
Recently, Morello et al. (14) showed that the cell-surface
expression of several V2R mutants of class II could be rescued
by cell-permeable V2R antagonists. Here, we found that all
nine V2R mutations studied were of this class, of which six
(L44P, R113W, I130F, S167T, G201D, T204N) turned out to
be able to translate AVP binding into a cAMP response.
Therefore, identifying cell-permeable pharmacological chaper-
ones that are able to rescue these six mutants may eventually
lead to a specific treatment to relieve NDI patients harboring
functional class II V2R mutations from their disease.
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